RxDoctor Payments Data

Antonios Katsigiannis, MD

Internal Medicine · Stamford, CTNPI 1629157276

Payments from drug & device makers

$21,755in general payments, 2019–2025

Across 935 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • Merck$870
  • Pfizer$822
  • plus $10K from 42 others

What the payments were for

  • Food & beverage$21,707100%
  • Education$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,755 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$36,301
Medicare patients
89
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$49,583
JardianceEmpagliflozin35$45,895
GlyxambiEmpagliflozin/Linagliptin24$30,687
FarxigaDapagliflozin Propanediol22$26,980
JanumetSitagliptin Phos/Metformin Hcl20$24,334
JanuviaSitagliptin Phosphate12$20,189
OzempicSemaglutide15$17,623
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,563
ProzacFluoxetine Hcl13$14,597
Xigduo XrDapaglifloz Propaned/Metformin16$14,416
OxycontinOxycodone Hcl15$11,471
NuedextaDextromethorphan Hbr/Quinidine11$8,176
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,740
VascepaIcosapent Ethyl11$6,613
Rosuvastatin Calcium246$3,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$1,327$76,58259 claims
PfizerEliquis$822$49,58354 claims
MerckJanumet, Januvia$870$44,52332 claims
AstraZenecaFarxiga$2,384$26,98022 claims
Novo NordiskOzempic$1,124$17,62315 claims
GSKTrelegy Ellipta$423$17,56320 claims
Avanir Pharmaceuticals, Inc.Nuedexta$131$8,17611 claims
AbbVieSynthroid$5,405$3,76335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →